Press Archive - Arriello

Pharmacovigilance under scrutiny.

Despite pharmacovigilance legislation being in place for nearly a decade, many companies are still struggling to fulfill obligations. Arriello's Vanessa Fachada Oliveira writes for Pharmaceutical Technology

Streamlining Pharmacovigilance.

Streamlining Pharmacovigilance: Why the Inertia? via Pharmaceutical Executive and Arriello's Director of Drug Safety Peter Kohut analyse the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Raising the bar in pharmacovigilance and regulatory outsourcing.

It’s all too easy to underestimate the importance of tight project management when the work being outsourced is something other than clinical trials. Yet, whether the processes involved concern international pharmacovigilance or regulatory information filing, Anna Lukyanova, COO of Arriello, warns life sciences firms not to leave outcomes to chance.

Streamlining Pharmacovigilance.

Automating PV Data Capture: What’s stopping Companies?

Proven solutions exist now which could transform the efficiency, effectiveness and regulatory adherence of PV processes, without placing data at any risk of being compromised in any way. By John Price – Pharmacovigilance expert and advisor to Arriello.

Money Isn’t Everything: Beating Salary Inflation.

Alan White, CEO of Arriello, explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.

Regulatory Process Innovation & The Dangers of Over-Promising with AI.

Never previously at the forefront of technology innovation, the life sciences industry now accepts that it needs to transform its agility, responsiveness and cost-efficiency, and that advanced digital tools are likely to form an important part of that strategy. Advanced digital tools are certain to play a pivotal role in the redesign of labour-intensive regulatory processes, but there is a danger that AI's potential contribution is being over-hyped. Arriello's CEO Alan White warns that the key to ROI is in the application...

Accelerating Industry Consolidation Leaves Dwindling Choices for Patients & SME Firms.

Merger & acquisition activity continues to be rife in life sciences, which is harming competition and reducing choice, both for patients and for more modest-sized pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements. Alan White assesses the impact.